NAD+ SubQ vs IV vs Oral: What the Bioavailability Data Actually Shows

Intravenous NAD+ administration delivers the molecule directly into systemic circulation, bypassing all first-pass metabolism and gut absorption variables. IV protocols in research settings typically run 500-1000mg over 2-4 hours, with slower infusion rates associated with fewer side effects (flushing, muscle cramping, and nausea are common at higher infusion rates). The dramatic improvement in cellular energy that many researchers report from IV NAD+ is consistent with the spike in circulating NAD+ and its rapid uptake into peripheral tissues, particularly skeletal muscle and neural tissue.

The practical limitation is access and cost. IV administration requires clinical supervision for higher doses due to cardiovascular side effects at fast infusion rates. For researchers seeking the NAD+ effect without clinical infrastructure, subcutaneous injection has emerged as the most practical alternative.

Subcutaneous NAD+ injection delivers the molecule into the interstitial space, from which it is absorbed into local capillaries over 20-40 minutes. Bioavailability studies comparing SubQ to IV suggest 60-75% relative bioavailability for subcutaneous NAD+ at equivalent doses, with a more gradual peak and longer plateau than IV delivery. This pharmacokinetic profile may be advantageous for sustained sirtuin activation compared to the sharp spike-and-fall of IV.

The key variable with SubQ NAD+ is injection site tolerance. NAD+ in solution is mildly acidic and can cause localized stinging and redness at the injection site, particularly at doses above 50mg. Rotating injection sites and reconstituting at appropriate concentrations (not too high) substantially reduces this. The standard 500mg vial reconstituted in 3mL BAC water yields 167mg/mL - a 50mg dose draws only 0.3mL, which is manageable.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are oral NAD+ precursors that raise circulating NAD+ by providing upstream substrates in the biosynthesis pathway. NMN enters cells via a specific transporter (Slc12a8) that is enriched in the gut, while NR is phosphorylated intracellularly to NMN and then to NAD+. Human trials of NMN at 250-500mg orally show measurable increases in whole-blood NAD+ at 2-4 weeks, with the increase in the range of 40-60% from baseline.

The practical argument for oral precursors is convenience and cost. The argument against, relative to injectable NAD+, is indirect delivery - you are providing a substrate and relying on the body's enzymatic machinery to complete the synthesis. In older subjects, the efficiency of this machinery is reduced due to lower NAMPT (the rate-limiting enzyme in the NAD+ salvage pathway) expression. This is precisely the population that most longevity researchers are targeting, which is why injectable NAD+ has retained research interest despite the availability of oral precursors.